Stock of Cogent Biosciences, Inc. (COGT) is falling about 6 percent on Wednesday morning trading after the submission of its New Drug Application to the U.S. Food and Drug Administration for bezuclastinib in patients with Gastrointestinal Stromal Tumors.
The company's stock is currently trading at $35.86, down 6.86 percent or $2.63, over the previous close of $38.50 on the Nasdaq. It has traded between $3.72 and $43.73 in the past one year.
Backed by the positive findings from the PEAK trial, the bezuclastinib NDA was submitted under the FDA's Real-Time Oncology Review program.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.